CA2380312A1 - Formulations for parenteral use of estramustine phosphate and albumin - Google Patents

Formulations for parenteral use of estramustine phosphate and albumin Download PDF

Info

Publication number
CA2380312A1
CA2380312A1 CA002380312A CA2380312A CA2380312A1 CA 2380312 A1 CA2380312 A1 CA 2380312A1 CA 002380312 A CA002380312 A CA 002380312A CA 2380312 A CA2380312 A CA 2380312A CA 2380312 A1 CA2380312 A1 CA 2380312A1
Authority
CA
Canada
Prior art keywords
estramustine phosphate
human albumin
cancer
formulation according
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380312A
Other languages
English (en)
French (fr)
Inventor
Paolo Colombo
Lorena Muggetti
Alessandro Martini
Giovanni Buzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT1999MI001998 external-priority patent/IT1313629B1/it
Application filed by Individual filed Critical Individual
Publication of CA2380312A1 publication Critical patent/CA2380312A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002380312A 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin Abandoned CA2380312A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9918779.1 1999-08-09
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
ITMI99A001998 1999-09-27
IT1999MI001998 IT1313629B1 (it) 1999-09-27 1999-09-27 Formulazioni di estramustina fosfato ed albumina per uso parenterale
PCT/EP2000/007678 WO2001010446A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Publications (1)

Publication Number Publication Date
CA2380312A1 true CA2380312A1 (en) 2001-02-15

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380312A Abandoned CA2380312A1 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Country Status (17)

Country Link
EP (1) EP1206266A2 (es)
JP (1) JP2003506408A (es)
KR (1) KR20020019967A (es)
CN (1) CN1511037A (es)
AU (1) AU6280900A (es)
BR (1) BR0013276A (es)
CA (1) CA2380312A1 (es)
CZ (1) CZ2002376A3 (es)
EA (1) EA200200234A1 (es)
HU (1) HUP0202645A3 (es)
IL (1) IL147745A0 (es)
MX (1) MXPA02001395A (es)
NO (1) NO20020631D0 (es)
NZ (1) NZ517632A (es)
PL (1) PL353406A1 (es)
SK (1) SK1782002A3 (es)
WO (1) WO2001010446A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (ko) * 2002-03-16 2004-04-13 박래옥 구연산, 알부민 및 아연을 함유한 항암 조성물
ES2685436T3 (es) * 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
HUP0202645A3 (en) 2004-06-28
WO2001010446A3 (en) 2001-05-25
IL147745A0 (en) 2002-08-14
NO20020631L (no) 2002-02-08
SK1782002A3 (en) 2002-05-09
EA200200234A1 (ru) 2002-06-27
CZ2002376A3 (cs) 2002-06-12
MXPA02001395A (es) 2002-08-12
EP1206266A2 (en) 2002-05-22
NO20020631D0 (no) 2002-02-08
JP2003506408A (ja) 2003-02-18
PL353406A1 (en) 2003-11-17
KR20020019967A (ko) 2002-03-13
BR0013276A (pt) 2004-08-03
WO2001010446A2 (en) 2001-02-15
AU6280900A (en) 2001-03-05
HUP0202645A2 (hu) 2002-12-28
CN1511037A (zh) 2004-07-07
NZ517632A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
EP1214078B1 (en) Formulations for parenteral use of estramustine phosphate and amino acids
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
CA2380312A1 (en) Formulations for parenteral use of estramustine phosphate and albumin
AU777763B2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis

Legal Events

Date Code Title Description
FZDE Discontinued